Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 ...

Moderna Inc. (NASDAQ: MRNA) is advancing its vaccine portfolio, with regulatory submissions underway for its seasonal ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

An update from Moderna ( (MRNA) ) is now available.

Moderna, Inc. is a biotechnology company specializing in the discovery and development of mRNA-based medicines. The company leverages its mRNA technology platform to address a broad range of diseases, ...

Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported ...